₹2,590.4
▼ -117.52 -4.34%
As of 28 Jul 2026 · delayed
NSE Listed · Pharmaceuticals
Kwality Pharmaceuticals Limited (KPL)
Volume: 26,342Avg Vol 1W: 23,733Avg Vol 1M: 31,51352W Range:₹1,561₹2,890.3
Key Ratios
Checked just nowMarket Cap₹2,688 Cr
Current Price₹2,590.4
Previous Close₹2,707.92
High / Low (52w)₹2,890.3 / ₹1,561
Volume26,342
Avg Vol (1W)23,733
Avg Vol (1M)31,513
Stock P/E39.55
Book Value₹319.46
Dividend Yield0%
ROE20.31%
ROA11.37%
Revenue (TTM)—
Revenue Growth—
Profit Margin13.39%
Total Debt—
Shares Outstanding1 Cr
Face Value₹10
EPS (TTM)₹24.39
P/B8.11
Debt / Equity0.43
50 DMA₹2,467.87
200 DMA—
Day change-4.34%
Price Chart
₹2,590.4▲ 55.80% · 1Y
2026-04-202026-07-28
20-day avg volume: 24K shares
Pros
- Healthy return on equity of 20.3%.
- Company is almost debt-free.
- Revenue grew 27% YoY.
- Net profit is growing year over year.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹80 Cr | ₹90 Cr | ₹84 Cr | ₹116 Cr | ₹111 Cr | ₹111 Cr | ₹123 Cr | ₹157 Cr |
| EBITDA | ₹14 Cr | ₹15 Cr | ₹14 Cr | ₹22 Cr | ₹20 Cr | ₹21 Cr | ₹26 Cr | ₹35 Cr |
| Net Profit | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹14 Cr | ₹12 Cr | ₹14 Cr | ₹16 Cr | ₹25 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹90 Cr | ₹84 Cr | ₹116 Cr | ₹372 Cr | ₹111 Cr | ₹111 Cr | ₹123 Cr | ₹157 Cr |
| EBITDA | ₹15 Cr | ₹14 Cr | ₹22 Cr | ₹64 Cr | ₹20 Cr | ₹21 Cr | ₹26 Cr | ₹35 Cr |
| Net Profit | ₹8 Cr | ₹9 Cr | ₹15 Cr | ₹40 Cr | ₹12 Cr | ₹14 Cr | ₹16 Cr | ₹25 Cr |
| EPS | — | — | — | 38.36 | — | — | — | — |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹96 Cr | ₹105 Cr | ₹133 Cr | ₹166 Cr | ₹341 Cr | ₹354 Cr | ₹394 Cr | ₹447 Cr |
| Total Liabilities | ₹67 Cr | ₹69 Cr | ₹88 Cr | ₹106 Cr | ₹161 Cr | ₹155 Cr | ₹172 Cr | ₹185 Cr |
| Equity | ₹29 Cr | ₹36 Cr | ₹45 Cr | ₹60 Cr | ₹180 Cr | ₹199 Cr | ₹223 Cr | ₹262 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹2 Cr | ₹17 Cr | ₹9 Cr | ₹33 Cr | ₹102 Cr | ₹48 Cr | ₹44 Cr | ₹69 Cr |
| Investing | ₹-6 Cr | ₹-12 Cr | ₹-18 Cr | ₹-23 Cr | ₹-63 Cr | ₹-48 Cr | ₹-26 Cr | ₹-29 Cr |
| Financing | ₹5 Cr | ₹-2 Cr | ₹12 Cr | ₹1 Cr | ₹6 Cr | ₹1 Cr | ₹-17 Cr | ₹-14 Cr |
| Free Cash Flow | ₹2 Cr | ₹17 Cr | ₹9 Cr | ₹33 Cr | ₹102 Cr | ₹48 Cr | ₹44 Cr | ₹69 Cr |
Shareholding
Promoter 54.86% Institutions 3.69% Public 41.44%
Efficiency & Working Capital
ROCE21.5%
Interest Coverage6.5
Dividend Payout—
Debtor Days152 d
Inventory Days82 d
Payable Days55 d
Cash Conversion Cycle179 d
Working Capital Days234 d
Shareholding Details
As of 2026-06-30
Promoter54.9%
FII3.1%
DII0.6%
Institutions3.7%
Public41.4%
Promoter Pledge0%
No. of Shareholders13,279
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 54.8% | 54.8% | 54.8% | 54.8% | 54.8% | 54.8% | 54.8% | 54.8% | 54.8% | 54.8% | 54.9% | 54.9% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.5% | 2.8% | 3.1% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% | 0.6% |
| Public | 45.2% | 45.2% | 45.2% | 45.2% | 45.2% | 45.1% | 44.9% | 44.8% | 44.8% | 44.3% | 42% | 41.4% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 6,291 | 5,786 | 5,695 | 5,273 | 7,487 | 8,947 | 9,420 | 10,115 | 11,595 | 10,709 | 10,555 | 13,279 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Ramesh Arora | Shareholding of Promoter and Promoter Group | 26% | 27,00,632 |
| Ajay Arora | Shareholding of Promoter and Promoter Group | 13.6% | 14,11,579 |
| Aditya Arora | Shareholding of Promoter and Promoter Group | 12% | 12,41,039 |
| Deepak Bansal | Public Shareholding | 8.4% | 8,70,160 |
| Manohar Devabhaktuni | Public Shareholding | 5% | 5,16,735 |
| Ark Global Emerging Companies, Lp | Public Shareholding | 2.1% | 2,18,896 |
| Kadayam Ramnathan Bharat | Public Shareholding | 2% | 2,05,000 |
| Dheeraj Kumar Lohia | Public Shareholding | 1.7% | 1,72,454 |
| Jani Bhasha Shaik | Public Shareholding | 1.5% | 1,50,000 |
| Anju Arora | Shareholding of Promoter and Promoter Group | 1.3% | 1,35,634 |
| Onkar Singh | Public Shareholding | 1.1% | 1,13,200 |
| Geeta Arora | Shareholding of Promoter and Promoter Group | 1.1% | 1,11,500 |
| Jugal Kishore Huf | Shareholding of Promoter and Promoter Group | 0.9% | 92,350 |
| Aarti Bajaj | Shareholding of Promoter and Promoter Group | 0% | 125 |
| Sachin Seth | Shareholding of Promoter and Promoter Group | 0% | 10 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Ramesh Arora | Executive Director & MD | 2025 |
| Ajay Arora | E D & Wholetime Director | 2025 |
| Aditya Arora | Executive Director / Whole Time Director / CFO | 2025 |
| Geeta Arora | E D & Wholetime Director | 2025 |
| Anju Arora | E D & Wholetime Director | 2025 |
| Kartik Kapur | Independent Non Exe. Director | 2025 |
| Prashanth Vellanki | Independent Non Exe. Director | 2025 |
| Vinod Kumar Sharma | Independent Non Exe. Director | 2025 |
| Gurpreet Kaur | Company Sec. & Compli. Officer | 2025 |
| Bhavesh Mahajan | Independent Non Exe. Director | 2025 |
| Preet Mohinder S Bedi | Independent Non Exe. Director | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| Export | ₹195 Cr | 52.8% |
| Domestic | ₹175 Cr | 47.2% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 16 | 10 | 10 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 5 | 0 | 0 | 3 | 0 | 8 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 5 | 0 | 0 | 3 | 0 | 8 |
Insider / Designated-Person Trades
4 recent disclosure(s)
Aastha SethAcquisition · 1,000
RAMESH KUMARAcquisition · 1,948
AJAY KUMAR ARORAAcquisition · 941
ADITYA ARORAAcquisition · 948
Substantial Acquisitions (SAST)
6 disclosure(s)
Market16/02/2024 · 1,200
Market15/02/2024 · 4,919
Market30/06/2023 · 1,04,000
-27/06/2023 · 5,18,810
Market24/05/2023 - 08/06/2023 · 3,02,000
NULL15/12/2021 · 25,620
Company Information
🌐 www.kwalitypharma.com ↗
📍 Village Nagkalan, Majitha Road, Amritsar, Punjab, 143601
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Kotyark Industries Ltd.Kovai Medical Center & Hospital Ltd.KP Energy LimitedKPI Green Energy LimitedKalpataru Projects International Ltd.KPIT TechnologiesK P R Mill Ltd.KRBL LimitedKrebs Biochemicals & Industries Ltd.Kridhan Infra LimitedKrishana Phoschem LimitedKrishca Strapping Solutions Ltd.All “K” stocks →
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search